Skip to main content
Erschienen in: Medical Oncology 4/2011

01.12.2011 | Original Paper

Nephrotic syndrome induced by pamidronate

verfasst von: M. A. G. J. ten Dam, L. B. Hilbrands, J. F. M. Wetzels

Erschienen in: Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Two patients developed nephrotic syndrome and progressive loss of renal function following treatment with i.v. pamidronate. Renal biopsy revealed collapsing focal segmental glomerulosclerosis (FSGS) in both the patients. In one patient, renal function recovered and the nephrotic syndrome disappeared after discontinuation of pamidronate. The second patient became dialysis dependent despite discontinuation of therapy. Nephrotic syndrome due to collapsing FSGS is a serious complication of treatment with bisphosphonates, especially of i.v. pamidronate. Bisphosphonates may also cause renal insufficiency as a result of tubular toxicity. In order to prevent severe nephrotoxicity clinicians should check urinary protein excretion and renal function regularly in patients who receive long-term treatment with i.v. bisphosphonates. In patients with pre-existing renal impairment (estimated GFR below 30 ml/min), bisphosphonates should be used with caution.
Literatur
1.
Zurück zum Zitat Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488–93.PubMedCrossRef Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488–93.PubMedCrossRef
2.
Zurück zum Zitat Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16(6):2038–44.PubMed Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16(6):2038–44.PubMed
3.
Zurück zum Zitat Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 2005;66(5):1054–9.PubMedCrossRef Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 2005;66(5):1054–9.PubMedCrossRef
4.
Zurück zum Zitat Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005;23(32):8219–24.PubMedCrossRef Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005;23(32):8219–24.PubMedCrossRef
5.
Zurück zum Zitat Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897–907.PubMedCrossRef Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897–907.PubMedCrossRef
6.
Zurück zum Zitat K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266.
7.
Zurück zum Zitat D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368–82.PubMedCrossRef D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368–82.PubMedCrossRef
8.
Zurück zum Zitat Schwimmer JA, Markowitz GS, Valeri A, Appel GB. Collapsing glomerulopathy. Semin Nephrol. 2003;23(2):209–18.PubMedCrossRef Schwimmer JA, Markowitz GS, Valeri A, Appel GB. Collapsing glomerulopathy. Semin Nephrol. 2003;23(2):209–18.PubMedCrossRef
9.
Zurück zum Zitat Deegens JK, Steenbergen EJ, Borm GF, Wetzels JF. Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population–epidemiology and outcome. Nephrol Dial Transplant. 2008;23(1):186–92.PubMedCrossRef Deegens JK, Steenbergen EJ, Borm GF, Wetzels JF. Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population–epidemiology and outcome. Nephrol Dial Transplant. 2008;23(1):186–92.PubMedCrossRef
10.
Zurück zum Zitat Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164–72.PubMed Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164–72.PubMed
11.
Zurück zum Zitat Desikan R, Veksler Y, Raza S, et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol. 2002;119(2):496–9.PubMedCrossRef Desikan R, Veksler Y, Raza S, et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol. 2002;119(2):496–9.PubMedCrossRef
12.
Zurück zum Zitat Kunin M, Kopolovic J, Avigdor A, Holtzman EJ. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant. 2004;19(3):723–6.PubMedCrossRef Kunin M, Kopolovic J, Avigdor A, Holtzman EJ. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant. 2004;19(3):723–6.PubMedCrossRef
13.
Zurück zum Zitat Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004;65(2):634–41.PubMedCrossRef Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004;65(2):634–41.PubMedCrossRef
14.
Zurück zum Zitat Shreedhara M, Fenves AZ, Benavides D, Stone MJ. Reversibility of pamidronate-associated glomerulosclerosis. Proc (Bayl Univ Med Cent). 2007;20(3):249–53. Shreedhara M, Fenves AZ, Benavides D, Stone MJ. Reversibility of pamidronate-associated glomerulosclerosis. Proc (Bayl Univ Med Cent). 2007;20(3):249–53.
15.
Zurück zum Zitat Jotterand V, Moll S, Martin P-Y, Saudan P. Bisphosphonates-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review. Nephrologie & Therapeutique. 2009;5:134. Jotterand V, Moll S, Martin P-Y, Saudan P. Bisphosphonates-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review. Nephrologie & Therapeutique. 2009;5:134.
16.
Zurück zum Zitat Nagahama M, Sica DA. Pamidronate-induced kidney injury in a patient with metastatic breast cancer. Am J Med Sci. 2009;338(3):225–8.PubMedCrossRef Nagahama M, Sica DA. Pamidronate-induced kidney injury in a patient with metastatic breast cancer. Am J Med Sci. 2009;338(3):225–8.PubMedCrossRef
17.
Zurück zum Zitat Markowitz GS, Fine PL, D’Agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis. 2002;39(5):1118–22.PubMedCrossRef Markowitz GS, Fine PL, D’Agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis. 2002;39(5):1118–22.PubMedCrossRef
18.
Zurück zum Zitat Gokden N, Zangari M, Elici F, Barlogie B, Kumar J. Potential effect of zoledronate therapy in heavy proteinuria. Clin Nephrol. 2007;67(4):263–5.PubMed Gokden N, Zangari M, Elici F, Barlogie B, Kumar J. Potential effect of zoledronate therapy in heavy proteinuria. Clin Nephrol. 2007;67(4):263–5.PubMed
19.
Zurück zum Zitat Pascual J, Torrealba J, Myers J, et al. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int. 2007;18(10):1435–8.PubMedCrossRef Pascual J, Torrealba J, Myers J, et al. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int. 2007;18(10):1435–8.PubMedCrossRef
20.
Zurück zum Zitat Bodmer M, Amico P, Mihatsch MJ, et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant. 2007;22(8):2366–70.PubMedCrossRef Bodmer M, Amico P, Mihatsch MJ, et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant. 2007;22(8):2366–70.PubMedCrossRef
21.
Zurück zum Zitat Hiroi-Furuya E, Kameda T, Hiura K, et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int. 1999;64(3):219–23.PubMedCrossRef Hiroi-Furuya E, Kameda T, Hiura K, et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int. 1999;64(3):219–23.PubMedCrossRef
22.
Zurück zum Zitat Sauter M, Julg B, Porubsky S, et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis. 2006;47(6):1075–80.PubMedCrossRef Sauter M, Julg B, Porubsky S, et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis. 2006;47(6):1075–80.PubMedCrossRef
23.
Zurück zum Zitat Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–9.PubMedCrossRef Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–9.PubMedCrossRef
24.
Zurück zum Zitat Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z. Pamidronate-induced nephrotoxic tubular necrosis–a case report. Clin Nephrol. 2004;61(1):63–7.PubMed Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z. Pamidronate-induced nephrotoxic tubular necrosis–a case report. Clin Nephrol. 2004;61(1):63–7.PubMed
25.
Zurück zum Zitat Buysschaert M, Cosyns JP, Barreto L, Jadoul M. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant. 2003;18(4):826–9.PubMedCrossRef Buysschaert M, Cosyns JP, Barreto L, Jadoul M. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant. 2003;18(4):826–9.PubMedCrossRef
26.
Zurück zum Zitat Janssen van DK, Neyns B, Van der NP, Verbeelen D. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron. 2001;89(4):467–8.CrossRef Janssen van DK, Neyns B, Van der NP, Verbeelen D. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron. 2001;89(4):467–8.CrossRef
27.
Zurück zum Zitat Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735–44.PubMedCrossRef Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735–44.PubMedCrossRef
28.
Zurück zum Zitat McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol. 2006;4(10):524–9.PubMed McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol. 2006;4(10):524–9.PubMed
29.
Zurück zum Zitat Diel IJ, Weide R, Köppler H, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical record review. Support Care Cancer. 2009;17:719–25.PubMedCrossRef Diel IJ, Weide R, Köppler H, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical record review. Support Care Cancer. 2009;17:719–25.PubMedCrossRef
30.
Zurück zum Zitat Bergner R, Diel IJ, Henrich D, Hoffman M, Uppenkamp M. Differences in nephrotoxicity of intravenous bisphophonates for the treatment of malignancy related bone disease. Onkologie. 2006;29:534–40.PubMedCrossRef Bergner R, Diel IJ, Henrich D, Hoffman M, Uppenkamp M. Differences in nephrotoxicity of intravenous bisphophonates for the treatment of malignancy related bone disease. Onkologie. 2006;29:534–40.PubMedCrossRef
31.
Zurück zum Zitat Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist. 2005;19:3–7.CrossRef Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist. 2005;19:3–7.CrossRef
32.
Zurück zum Zitat American Society of Clinical Oncology. Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464–72.CrossRef American Society of Clinical Oncology. Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464–72.CrossRef
33.
Zurück zum Zitat Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105–15.PubMedCrossRef Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105–15.PubMedCrossRef
Metadaten
Titel
Nephrotic syndrome induced by pamidronate
verfasst von
M. A. G. J. ten Dam
L. B. Hilbrands
J. F. M. Wetzels
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9628-7

Weitere Artikel der Ausgabe 4/2011

Medical Oncology 4/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.